PSMA-11 is a small-molecule ligand that binds specifically to prostate-specific membrane antigen (PSMA), acting as a PSMA inhibitor. It serves as a precursor for synthesizing ⁶⁸Ga-PSMA-11, a PET imaging tracer widely used in the detection of advanced prostate cancer.

Application: Precursor for [⁶⁸Ga]DKFZ-GaPSMA-11
Molecular weight: 946.99

-Care must be taken when handling this product.
-Do not contact skin or eyes.
-Do not ingest or inhale.
-Store at <-20℃. Protect from light.(Short-term storage (<1 month) at higher temperatures (e.g. during transport) does not affect product quality)
-It shall be only used by qualified personnel and only for research.

PSMA11-97-0.05x       0.05mg per vial
PSMA11-97-0.5x       0.5mg per vial
PSMA11-97-0001x       1mg per vial
note: x includes A B C and D, A refers to 2ml vial; B refers to 4.5ml vial; C refers to 8ml vial; D refers to 30ml vial
*Customized dispensing is available

Literature
1.Fuscaldi, L. L., Paiva, I., Cardoso, V. N., Lima, K. M. A., & Ferreira, L. C. (2021).Standardization of the [⁶⁸Ga]Ga‑PSMA‑11 Radiolabeling Protocol in an Automatic Synthesis Module. Pharmaceuticals, 14(5), 385. 
2.Iudicello, A., Bosco, F., Botta, M., Migliari, S., & Di Muzio, N. (2022). Optimization of Precursor Preparation in PSMA-11 Radiolabeling to Obtain a Highly Reproducible Radiochemical Yield. Journal of Labelled Compounds and Radiopharmaceuticals, 65(8), 324–330.